Opthea Limited CKDXF

Annual Quarterly

FY2025 · ended Jun 30, 2025 · Revenue $25,000, -80.0% YoY · Filed Sep 15, 2025

Opthea Limited (CKDXF) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In fiscal 2025, which ended Jun 30, 2025, it reported revenue of $25,000 and a net loss of $162.8 million. Free cash flow was -$158.7 million. As of Jun 30, 2025 it held $48.4 million in cash and investments and $9.7 million in total debt.

Revenue
$25,000
-80.0% vs prior year
Net income
$-162.79M
+26.1% vs prior year
Operating cash flow
$-158.64M
+1.5% vs prior year
Free cash flow
$-158.66M
+1.5% vs prior year
EPS
$-0.13
+61.5% vs prior year
Dividend per share
None
Shares outstanding
—
Net cash
$38.71M
FY 2025
Operating margin
-623048.0%
FY 2025

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
CKDXF (OTC), CYVNY (OTC)
Fiscal year ends
June 30
Incorporated in
Australia
Headquarters
South Yarra
SEC filer status
Non-accelerated filer, Emerging growth company
SEC CIK
1815620

Other Biological Products, (No Diagnostic Substances) companies

Key figures

Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.

Line
FY 2025
Jun 30, 2025
FY 2024
Jun 30, 2024
FY 2023
Jun 30, 2023
FY 2022
Jun 30, 2022
FY 2021
Jun 30, 2021
Revenue
$25,000
$125,000
$108,000
$90,683
$68,613
Operating income
-$155.8M
-$191.8M
—
—
—
Net income
-$162.8M
-$220.2M
-$142.5M
-$92.8M
-$45.3M
Diluted EPS
-$0.13
-$0.35
-$0.32
—
—
Operating cash flow
-$158.6M
-$161.0M
-$120.6M
-$71.3M
-$45.5M
Free cash flow
-$158.7M
-$161.0M
-$120.6M
-$71.4M
-$45.6M
Total assets
$56.8M
$188.8M
$98.6M
$60.0M
$138.4M
Total liabilities
$257.9M
$264.6M
$104.5M
$12.1M
$3.1M
Stockholders' equity
-$201.1M
-$75.8M
-$5.9M
$48.0M
$135.3M
Cash and investments
$48.4M
$172.5M
$89.2M
$44.6M
$118.2M
Total debt
$9.7M
$38.2M
$18.0M
$11.4M
$2.5M

Recent SEC filings

Recent SEC filings
Form Description Filed Period
6-K Current report (foreign issuer) Nov 20, 2025 Nov 20, 2025
6-K Current report (foreign issuer) Nov 12, 2025 Nov 12, 2025
6-K Current report (foreign issuer) Oct 31, 2025 Oct 31, 2025
6-K Current report (foreign issuer) Oct 30, 2025 Oct 30, 2025
6-K Current report (foreign issuer) Oct 27, 2025 Oct 27, 2025
6-K Current report (foreign issuer) Oct 10, 2025 Oct 10, 2025

Source: SEC EDGAR filings. This is company-reported data, not investment advice.